Celyad Oncology SA American Depositary Shares
CYAD
CYAD was delisted on the 18th of May, 2023.
1 hedge funds and large institutions have $5.9K invested in Celyad Oncology SA American Depositary Shares in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
36% less capital invested
Capital invested by funds: $9.27K → $5.9K (-$3.37K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
-$5.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
RhumbLine Advisers
Boston,
Massachusetts
| $5.9K | – | – | – |
|
|
BBA
2
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$5.67K | -18,277 | Closed |
|
CYAD Hedge Fund Activity: Q3 2023 in Review
1 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Celyad Oncology SA American Depositary Shares (CYAD) for Q3 2023, worth a combined $5.9K — down 36% from $9.27K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CYAD and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Baader Bank Aktiengesellschaft, exiting entirely with an estimated $5.67K sold.
- 1 institutional investor held Celyad Oncology SA American Depositary Shares (CYAD) as of Q3 2023, down from 2 in Q2 2023.
- Funds reported $5.9K of Celyad Oncology SA American Depositary Shares stock for Q3 2023, down 36% quarter-over-quarter.
- 0 funds opened new Celyad Oncology SA American Depositary Shares positions in Q3 2023 and 1 closed out, a net change of -1 holder.
- The largest Celyad Oncology SA American Depositary Shares seller in Q3 2023 was Baader Bank Aktiengesellschaft, an estimated $5.67K sold.
Based on aggregated 13F filings for Q3 2023.